TY - JOUR
T1 - Diffuse Lewy body disease manifesting as corticobasal syndrome A rare form of Lewy body disease
AU - Kasanuki, Koji
AU - Josephs, Keith A.
AU - Ferman, Tanis J.
AU - Murray, Melissa E.
AU - Koga, Shunsuke
AU - Konno, Takuya
AU - Sakae, Nobutaka
AU - Parks, Adam
AU - Uitti, Ryan J.
AU - Van Gerpen, Jay A.
AU - Graff-Radford, Neill R.
AU - Wszolek, Zbigniew K.
AU - Dickson, Dennis W.
N1 - Funding Information:
K. Kasanuki reports no disclosures relevant to the manuscript. K. Josephs is funded by NIH grants R01 AG037491 (principal investigator [PI]); R01 NS89757 (PI); and R21 NS094684 (PI). T. Ferman receives research support from the NIH (P50-AG016574) and from the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic. M. Murray, S. Koga, T. Konno, N. Sakae, and A. Parks report no disclosures relevant to the manuscript. R. Uitti receives research support by the NIH//NINDS (R01-NS057567), research funding from Advanced Neuromodulation Systems, Inc./St. Jude Medical, and a gift from Carl Edward Bolch, Jr., and Susan Bass Bolch. Dr. Uitti is an editorial board member of Neurology. J. Van Gerpen reports no disclosures relevant to the manuscript. N. Graff-Radford serves on a scientific advisory board for Codman; serves on the editorial boards of The Neurologist and Alzheimer’s Research & Therapy; has received publishing royalties from UpToDate, Inc.; and receives research support from Biogen, Lilly, and Axovant. He has consulted for Cytox. Z. Wszolek holds and has contractual rights for receipt of future royalty payments from patents re: A novel polynucleotide involved in heritable Parkinson’s disease; receives royalties from editing Parkinsonism and Related Disorders (Elsevier, 2015, 2016) and the European Journal of Neurology (Wiley-Blackwell, 2015, 2016). Dr. Wszolek is partially supported by the NIH/NINDS P50 NS072187, NIH/NIA (primary), and NIH/NINDS (secondary) U01AG045390; Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team (Cecilia and Dan Carmichael Family Foundation, and the James C. and Sarah K. Kennedy Fund for Neurodegenerative Disease Research at Mayo Clinic in Florida); the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch, The Sol Goldman Charitable Trust, and Donald G. and Jodi P. Heeringa. D. Dickson receives research support from the NIH (P50-AG016574; P50-NS072187; P01-AG003949), from the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic, and the Robert E. Jacoby Professorship. Dr. Dickson is an editorial board member of Acta Neuropathologica, Annals of Neurology, Brain, Brain Pathology, and Neuropathology, and he is editor in chief of American Journal of Neurodegenerative Disease. Go to Neurology.org/N for full disclosures.
Funding Information:
Supported by Mayo Clinic Alzheimer’s Disease Research Center (P50 AG16574); Udall Center of Excellence for Parkinson’s Disease Research (P50 NS72187); Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic; CurePSP; and The Tau Consortium. This study was supported by NIH (P50 NS072187, P50 AG016574, U54 NS100693), the Michael J. Fox Foundation, the Mayo Clinic Alzheimer’s Disease and Related Dementias Genetics Program, and by the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic.
Funding Information:
Supported by Mayo Clinic Alzheimer's Disease Research Center (P50 AG16574); Udall Center of Excellence for Parkinson's Disease Research (P50 NS72187); Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic; CurePSP; and The Tau Consortium. This study was supported by NIH (P50 NS072187, P50 AG016574, U54 NS100693), the Michael J. Fox Foundation, the Mayo Clinic Alzheimer's Disease and Related Dementias Genetics Program, and by the Mangurian Foundation Lewy Body Dementia Program at Mayo Clinic.
Publisher Copyright:
© 2018 American Academy of Neurology
PY - 2018/7/17
Y1 - 2018/7/17
N2 - Objective To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS). Methods In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intra-cytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex. Results DLBD patients with antemortem features of CBS were significantly younger at disease onset and less likely to have REM sleep behavior disorder than DLBD cases who met clinical criteria for DLB during life. Patients with DLBD manifesting as CBS had more Lewy bodies in the motor cortex than DLBD manifesting as clinically probable DLB. Three cases had concomitant progressive supranuclear palsy and 4 cases had concomitant Alzheimer disease as probable correlates of CBS. Conclusion The neuropathology underlying CBS is heterogeneous, including corticobasal degeneration, Alzheimer disease, and progressive supranuclear palsy. This study suggests that atypical variants of Lewy body disease with severe peri-Rolandic Lewy-related pathology can present clinically as CBS. Patients with DLBD who present as CBS tend to have an earlier age at onset and are less likely to have clinical features of DLB, such as dream enactment behavior during sleep, visual hallucinations, and levodopa-responsive parkinsonism. Future studies with biofluid or molecular imaging biomarkers for α-synuclein will permit better recognition of this uncommon pathologic substrate of CBS.
AB - Objective To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS). Methods In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intra-cytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex. Results DLBD patients with antemortem features of CBS were significantly younger at disease onset and less likely to have REM sleep behavior disorder than DLBD cases who met clinical criteria for DLB during life. Patients with DLBD manifesting as CBS had more Lewy bodies in the motor cortex than DLBD manifesting as clinically probable DLB. Three cases had concomitant progressive supranuclear palsy and 4 cases had concomitant Alzheimer disease as probable correlates of CBS. Conclusion The neuropathology underlying CBS is heterogeneous, including corticobasal degeneration, Alzheimer disease, and progressive supranuclear palsy. This study suggests that atypical variants of Lewy body disease with severe peri-Rolandic Lewy-related pathology can present clinically as CBS. Patients with DLBD who present as CBS tend to have an earlier age at onset and are less likely to have clinical features of DLB, such as dream enactment behavior during sleep, visual hallucinations, and levodopa-responsive parkinsonism. Future studies with biofluid or molecular imaging biomarkers for α-synuclein will permit better recognition of this uncommon pathologic substrate of CBS.
UR - http://www.scopus.com/inward/record.url?scp=85055023195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055023195&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000005828
DO - 10.1212/WNL.0000000000005828
M3 - Article
C2 - 29898972
AN - SCOPUS:85055023195
SN - 0028-3878
VL - 91
SP - E268-E279
JO - Neurology
JF - Neurology
IS - 3
ER -